MG-262

CAT: 0804-HY-108551Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-108551Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
MG-262 (Z-Leu-Leu-LeuB (OH) 2; ZL3B) is a reversible proteasome inhibitor. MG-262 down-regulates VEGF receptor Flt-1. MG-262 inhibits cell growth and induces apoptosis in malignant cells. MG-262 induces reactive oxygen species (ROS) . MG-262 can be used for anti-cancer study[1][2][3][4][5].
CAS Number
[179324-22-2]
Product Name Alternative
Z-Leu-Leu-LeuB (OH) 2; ZL3B
UNSPSC
12352005
Target
Apoptosis; Proteasome; Reactive Oxygen Species (ROS) ; VEGFR
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/mg-262.html
Purity
95.0
Solubility
DMSO : 5 mg/mL (ultrasonic)
Smiles
O=C(N[C@H](B(O)O)CC(C)C)[C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC1=CC=CC=C1)=O)=O
Molecular Formula
C25H42BN3O6
Molecular Weight
491.43
References & Citations
[1]Mezquita J, et al. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem. 2003 Aug 15;89 (6) :1138-47. |[2]Wu HM, et al. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett. 2002 Aug 28;526 (1-3) :101-5. |[3]Huang H, et al. Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Lett. 2011 Feb 28;301 (2) :221-8.|[4]Kumarapeli AR, et al A novel transgenic mouse model reveals deregulation of the ubiquitin-proteasome system in the heart by doxorubicin. FASEB J. 2005 Dec;19 (14) :2051-3.|[5]Lindsten K, et al. A transgenic mouse model of the ubiquitin/proteasome system. Nat Biotechnol. 2003 Aug;21 (8) :897-902.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products